TMCnet News
FORUM Pharmaceuticals Appoints Todd Shegog As Chief Financial Officer [Global Data Point](Global Data Point Via Acquire Media NewsEdge) Mr. Shegog, former Senior Vice President, Finance and Chief Financial Officer at Millennium Pharmaceuticals, Inc., now Millennium: The Takeda Oncology Company, brings to FORUM 20 years of financial experience in the biotechnology and pharmaceutical industries. "Todd's strong combination of leadership and financial experience in growing successful organizations should serve FORUM well as we continue building a fully sustainable company," said Deborah Dunsire, M.D., President and Chief Executive Officer of FORUM Pharmaceuticals. "FORUM is poised to potentially commercialize the first innovative therapies for schizophrenia and Alzheimer's disease in more than a decade, and we look forward to benefitting from Todd's experience. We anticipate that his skills will be a valuable resource in the financial management of our ongoing worldwide Phase 3 clinical trials for encenicline in schizophrenia and Alzheimer's disease and other active, earlier-stage investigational studies for diseases such as dementia." Prior to FORUM, Mr. Shegog served as Senior Vice President, Finance and Chief Financial Officer at Millennium Pharmaceuticals, Inc., now Millennium: The Takeda Oncology Company, where he was responsible for management of the company's financial resources, corporate planning, financial reporting and compliance. During his tenure from 1998 to 2014, Mr. Shegog held key leadership roles supporting the early evolution of the company and its transformation from a genomics company to a fully-integrated drug developer, the approval and launch of its flagship oncology product, VELCADE®, and the $8.8 billion acquisition of Millennium by Takeda Pharmaceuticals. He began his career in healthcare at Genetics Institute (now Pfizer) in a variety of financial positions supporting its research and development organizations, and was a member of the Commercial Operations team that supported the launch of BeneFIX®. Mr. Shegog holds an M.B.A. from the Tepper School of Management, Carnegie Mellon University and a B.S. degree in electrical engineering from Lafayette College. "I'm excited to be part of this enthusiastic and dynamic company, which is so clearly driven in its mission to leverage compelling science into developing new medicines to treat brain disease," said Mr. Shegog. "FORUM faces a pivotal stage of development as it continues to mature into a late-stage biotechnology company, and I'm eager that I can contribute my financial experience in working with this dedicated team at this important inflection point in the company's growth." (c) 2014 GlobalData Provided by Syndigate.info, an Albawaba.com company [ Back To TMCnet.com's Homepage ] |